AbbVie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial
By Kelly Cloonan
AbbVie and Genmab's drug combination for a type of lymphoma met the primary endpoint in a Phase 3 trial.
The companies said Monday the combination of epcoritamab and lenalidomide demonstrated statistically significant improvement in progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy, as compared to treatment with rituximab plus gemcitabine plus oxaliplatin.
In the trial, the drug combination reduced the risk of disease progression and death by about 60%, the companies said.
Diffuse large B-cell lymphoma is an aggressive and often difficult-to-treat cancer, AbbVie said.
The companies said they would engage with global regulatory authorities to discuss next steps for the treatment, and plan to submit the data for presentation at a future medical meeting.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
June 29, 2026 16:58 ET (20:58 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
Your 7-Figure Retirement Fund Might Not Stretch As Far As You Think. Here’s How to Change That
This Wide-Moat Stock Is Still a Buy After Its Rally
4 Undervalued Stocks to Buy for Income
6 Undervalued Stocks That Crushed Earnings
United States